Profile data is unavailable for this security.
About the company
Sinotherapeutics Inc is a China-based company mainly engaged in the research and development, product registration, production and sales of generic drugs, as well as contract research organization/contract manufacture organization (CRO/CMO) services. The Company's main products include posaconazole enteric-coated tablets, mesalazine enteric-coated tablets, ursodeoxycholic acid capsules and others. The Company's products cover multiple fields including antifungal, psychiatric, diabetes, cancer, digestive, hypertension, nephrology, and analgesia. The Company's CRO/CMO services are primarily formulation CRO/CMO services, providing pharmaceutical companies and research institutions with specialized formulation development services during drug development and commercial manufacturing services after drug approval through contracts. The Company mainly conducts its business in the domestic and overseas markets.
- Revenue in CNY (TTM)480.48m
- Net income in CNY98.59m
- Incorporated2012
- Employees312.00
- LocationSinotherapeutics IncSHANGHAI 201210ChinaCHN
- Phone+86 2 168819009
- Fax+86 2 168819009
- Websitehttps://www.sinotph.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jinyao Pharmaceutical Co Ltd | 2.87bn | 16.30m | 4.54bn | 2.88k | 272.43 | 1.50 | -- | 1.58 | 0.0153 | 0.0153 | 2.63 | 2.77 | 0.49 | 2.45 | 6.38 | 996,743.00 | 1.39 | 1.87 | 2.18 | 3.31 | 41.43 | 45.67 | 2.84 | 3.30 | 1.19 | 11.91 | 0.1563 | 65.00 | -15.00 | -0.6786 | 14.01 | -3.78 | -23.40 | 19.63 |
| Zhejiang Starry Pharmaceutical Co Ltd | 2.39bn | -29.25m | 4.57bn | 1.75k | -- | 1.76 | -- | 1.91 | -0.1149 | -0.1149 | 5.84 | 5.93 | 0.4078 | 1.78 | 5.62 | 1,363,012.00 | -0.4978 | 2.04 | -0.8498 | 3.75 | 18.98 | 27.73 | -1.22 | 5.05 | 0.4035 | 0.6728 | 0.5007 | 78.73 | 7.02 | 12.42 | -211.00 | -- | 29.24 | -3.43 |
| Yabao Pharmaceutical Group Co Ltd | 2.27bn | 222.85m | 4.58bn | 3.61k | 20.84 | 1.66 | -- | 2.02 | 0.3177 | 0.3177 | 3.26 | 3.99 | 0.6462 | 3.42 | 6.66 | 629,532.00 | 5.51 | 4.01 | 6.54 | 5.38 | 50.46 | 56.75 | 8.53 | 5.86 | 2.49 | -- | 0.0418 | 54.27 | -7.69 | -2.46 | 21.60 | 77.16 | -26.08 | 71.88 |
| Obio Technology Shanghai Corp Ltd | 244.64m | -294.16m | 4.60bn | 692.00 | -- | 3.02 | -- | 18.81 | -0.4578 | -0.4578 | 0.3819 | 2.35 | 0.1095 | 4.22 | 2.37 | 353,519.30 | -13.15 | -3.10 | -15.68 | -3.47 | -37.29 | 19.60 | -120.16 | -23.22 | 1.06 | -94.99 | 0.2068 | -- | 21.16 | 31.58 | -151.54 | -- | 36.17 | -- |
| Sinotherapeutics Inc | 480.48m | 98.59m | 4.63bn | 312.00 | 46.95 | 3.54 | -- | 9.63 | 0.2175 | 0.2175 | 1.06 | 2.89 | 0.333 | 2.74 | 4.51 | 1,539,987.00 | 6.83 | 10.22 | 7.32 | 11.26 | 43.78 | 65.76 | 20.52 | 31.88 | 11.08 | -- | 0.00002 | 13.77 | 70.61 | 29.80 | 109.09 | 94.07 | 32.01 | -- |
| Ningbo Menovo Pharmaceutical Co Ltd | 1.54bn | 99.48m | 4.67bn | 2.47k | 47.05 | 2.02 | -- | 3.03 | 0.4502 | 0.4502 | 7.00 | 10.49 | 0.329 | 1.23 | 5.91 | 623,207.90 | 2.34 | 3.98 | 3.68 | 6.21 | 32.03 | 34.08 | 7.11 | 12.00 | 0.7165 | 5.71 | 0.3482 | 11.27 | 12.85 | 3.07 | 476.64 | -15.04 | -11.37 | -8.68 |
| Shanghai Xiao Fang Pharmaceutical Co Ltd | 504.59m | 213.50m | 4.76bn | 404.00 | 22.17 | 4.51 | -- | 9.43 | 1.33 | 1.33 | 3.16 | 6.57 | 0.3795 | 3.71 | 4.85 | 1,248,981.00 | 16.06 | -- | 19.02 | -- | 65.40 | -- | 42.31 | -- | 3.47 | -- | 0.0017 | -- | 0.5748 | -- | 0.8074 | -- | -- | -- |
| Pulike Biological Engineering Inc | 1.10bn | 143.67m | 4.78bn | 1.55k | 32.87 | 1.86 | -- | 4.33 | 0.4204 | 0.4204 | 3.22 | 7.45 | 0.3571 | 2.68 | 3.03 | 711,690.80 | 4.65 | 6.79 | 5.41 | 8.00 | 57.65 | 62.55 | 13.02 | 16.34 | 2.51 | 15.83 | 0.0005 | 61.54 | -16.77 | 9.47 | -46.82 | -3.21 | 7.28 | 14.87 |
| Tibet Weixinkang Pharmaceutical Co Ltd | 1.17bn | 222.08m | 4.84bn | 689.00 | 21.67 | 3.17 | -- | 4.15 | 0.5136 | 0.5136 | 2.71 | 3.51 | 0.608 | 11.75 | 6.71 | 1,695,637.00 | 11.56 | 10.05 | 14.30 | 13.45 | 58.42 | 51.50 | 19.01 | 13.72 | 3.93 | -- | 0.0058 | 52.31 | -1.69 | 11.90 | 15.02 | 34.62 | 5.91 | 50.02 |
| Guizhou Sanli Pharmaceutical Co Ltd | 1.74bn | 160.68m | 4.90bn | 2.85k | 30.19 | 3.32 | -- | 2.82 | 0.3969 | 0.3969 | 4.26 | 3.61 | 0.5877 | 1.73 | 2.98 | 608,615.00 | 5.58 | 10.78 | 8.75 | 15.70 | 68.09 | 70.69 | 9.49 | 15.41 | 1.11 | 27.57 | 0.345 | 35.70 | 31.16 | 19.40 | -6.38 | 15.54 | 41.35 | -- |
Data as of Feb 13 2026. Currency figures normalised to Sinotherapeutics Inc's reporting currency: Chinese Yuan Renminbi CNY
1.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Haitong Innovation Securities Investment Co Ltd.as of 26 Aug 2025 | 2.27m | 0.50% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 1.42m | 0.31% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2025 | 410.00k | 0.09% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2025 | 363.00k | 0.08% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 314.26k | 0.07% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 251.84k | 0.06% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 240.84k | 0.05% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 158.49k | 0.04% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 121.83k | 0.03% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 93.83k | 0.02% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
